DP
PHAT icon

Diadema Partners’s Phathom Pharmaceuticals PHAT Stock Holding History

Diadema Partners’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.41M Buy
129,950
+75,300
+138% +$859K 0.18% 95
2026
Q1 		$607K Buy
+54,650
New +$690K 0.1% 102
2025
Q3 		– Sell
-40,294
Closed -$386K – 155
2025
Q2 		$386K Buy
+40,294
New +$223K 0.12% 80

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Diadema Partners's PHAT Position: Q2 2026 in Review

Diadema Partners increased its Phathom Pharmaceuticals (PHAT) stake by 138% in Q2 2026, buying an estimated $859K and bringing the position to 129,950 shares worth $1.41M. The position accounts for 0.18% of the portfolio, ranked #95.

Diadema Partners first reported a position in PHAT in Q2 2025 and has held it in 3 quarters since. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Diadema Partners held 129,950 shares of Phathom Pharmaceuticals worth $1.41M as of Q2 2026.
  • Diadema Partners bought 75,300 Phathom Pharmaceuticals shares in Q2 2026, an estimated $859K.
  • Phathom Pharmaceuticals made up 0.18% of Diadema Partners's portfolio in Q2 2026, its #95 holding.
  • Diadema Partners first reported a position in Phathom Pharmaceuticals in Q2 2025 and has held it in 3 quarters since.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.